Evolent Health Inc (NYSE:EVH) – Analysts at Jefferies Group dropped their FY2017 earnings per share (EPS) estimates for Evolent Health in a research note issued to investors on Tuesday, according to Zacks Investment Research. Jefferies Group analyst S. Dodge now forecasts that the technology company will post earnings per share of ($0.57) for the year, down from their prior estimate of ($0.56). Jefferies Group currently has a “Buy” rating and a $22.00 target price on the stock. Jefferies Group also issued estimates for Evolent Health’s Q1 2018 earnings at ($0.02) EPS, Q2 2018 earnings at ($0.02) EPS, Q3 2018 earnings at ($0.01) EPS, Q4 2018 earnings at ($0.01) EPS, FY2018 earnings at ($0.06) EPS and FY2019 earnings at $0.19 EPS.
Other research analysts have also recently issued research reports about the stock. Citigroup started coverage on shares of Evolent Health in a report on Thursday, January 4th. They issued a “buy” rating for the company. Cantor Fitzgerald reissued a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research note on Sunday, December 3rd. Leerink Swann set a $25.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a research note on Saturday, November 18th. Goldman Sachs Group cut shares of Evolent Health from a “conviction-buy” rating to a “buy” rating in a research note on Tuesday, November 7th. Finally, SunTrust Banks reissued a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $27.40.
Shares of Evolent Health (NYSE:EVH) traded up $0.20 during mid-day trading on Thursday, reaching $14.20. 226,740 shares of the company traded hands, compared to its average volume of 872,466. The stock has a market capitalization of $1,086.57, a price-to-earnings ratio of -12.39 and a beta of 1.24. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.11. Evolent Health has a 12 month low of $10.30 and a 12 month high of $27.50.
A number of large investors have recently bought and sold shares of EVH. Royal Bank of Canada increased its position in Evolent Health by 1,197.8% in the second quarter. Royal Bank of Canada now owns 8,293 shares of the technology company’s stock worth $210,000 after purchasing an additional 7,654 shares during the period. SG Americas Securities LLC bought a new stake in Evolent Health in the third quarter worth about $156,000. PNC Financial Services Group Inc. lifted its stake in Evolent Health by 245.2% in the second quarter. PNC Financial Services Group Inc. now owns 10,357 shares of the technology company’s stock worth $262,000 after purchasing an additional 7,357 shares during the last quarter. IPG Investment Advisors LLC bought a new stake in Evolent Health in the third quarter worth about $195,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Evolent Health in the third quarter worth about $205,000. Institutional investors own 96.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/22/jefferies-group-comments-on-evolent-health-incs-fy2017-earnings-evh.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Get a free copy of the Zacks research report on Evolent Health (EVH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.